Global Viscosupplementation Market by Treatment Type (Injections, Hyaluronic Acid-based Products, Non-Hyaluronic Acid-based Products), by Application (Osteoarthritis, Joint Pain Management, Sports Injuries), by End-Use Industry (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers) and By Region; Global Insights & Forecast (2023 - 2030)

As per Intent Market Research, the Viscosupplementation Market was valued at USD 4.8 billion in 2024-e and will surpass USD 17.0 billion by 2030; growing at a CAGR of 23.4% during 2025 - 2030.

The viscosupplementation market is witnessing significant growth due to the rising prevalence of osteoarthritis (OA) and other joint-related disorders, particularly among aging populations and active individuals. Viscosupplementation, which involves the injection of gel-like substances into the joint to restore synovial fluid, plays a crucial role in alleviating pain, improving mobility, and delaying or preventing the need for invasive surgeries like joint replacements. With advancements in injection techniques and the increasing awareness of joint health, the demand for viscosupplementation therapies is expanding, as they offer a less invasive and effective treatment alternative for joint pain management.

The market for viscosupplementation treatments is expanding globally, driven by increasing consumer awareness, the aging global population, and the growing incidence of musculoskeletal conditions. As patients seek alternatives to traditional pain management options such as opioids or invasive surgeries, viscosupplementation is gaining popularity for its ability to provide long-term relief. The growing interest in sports medicine and joint preservation further fuels market demand, as athletes and active individuals seek treatments that can help maintain joint function and prevent long-term damage.

Injections Segment is Largest Due to Direct and Effective Treatment

The injections segment is the largest within the viscosupplementation market, primarily due to the direct and highly effective approach to pain management that injections offer. Injections, including hyaluronic acid-based and non-hyaluronic acid-based products, provide rapid relief by delivering the active ingredients directly into the affected joint. This mode of treatment is particularly advantageous for patients who require immediate and targeted relief from conditions like osteoarthritis, joint pain, and sports injuries. The efficiency and localized action of injections make them the preferred choice for treating joint-related pain and discomfort.

The large market share of injections is also driven by their widespread use in various clinical settings, including hospitals, orthopedic clinics, and ambulatory surgical centers. With patients increasingly seeking non-surgical alternatives for joint pain management, injections remain a popular treatment option due to their minimally invasive nature and proven efficacy in reducing pain and improving joint function. The growth of the injections segment is expected to continue as research and innovation in viscosupplementation products lead to even more effective and longer-lasting solutions for joint care.

Hyaluronic Acid-based Products Segment is Fastest Growing Due to Efficacy and Popularity

The hyaluronic acid-based products segment is the fastest-growing within the viscosupplementation market, primarily driven by the increasing recognition of hyaluronic acid as an effective and safe treatment option for osteoarthritis and other joint disorders. Hyaluronic acid, a naturally occurring substance in the body, is used in viscosupplementation injections to restore the viscosity and elasticity of synovial fluid, which helps to lubricate and cushion the joints. This product type has gained widespread popularity due to its ability to provide significant pain relief and improve joint mobility, making it a first-line treatment for many patients with knee osteoarthritis and similar conditions.

Hyaluronic acid-based viscosupplementation is particularly attractive to patients because of its relatively low risk of side effects and the potential for long-lasting results, with many patients experiencing relief for several months after a single injection. As awareness grows about the benefits of hyaluronic acid for joint health, the demand for these products continues to rise. Additionally, ongoing research into the development of more advanced hyaluronic acid formulations, which promise better outcomes with fewer injections, is expected to further accelerate the growth of this segment.

Osteoarthritis Segment is Largest Application Due to High Prevalence of the Disease

The osteoarthritis segment is the largest application within the viscosupplementation market, driven by the high prevalence of OA, particularly in the elderly population. OA is a degenerative joint disease that occurs when the cartilage in the joints breaks down over time, leading to pain, stiffness, and reduced joint function. As the global population ages, the number of individuals suffering from OA is increasing, creating a significant demand for effective pain management solutions such as viscosupplementation. Given the chronic nature of OA and its impact on mobility and quality of life, viscosupplementation is a preferred treatment option for many patients.

Viscosupplementation offers OA patients an alternative to pain medications and invasive surgeries, allowing them to manage symptoms and improve joint function. This treatment is especially beneficial for patients with mild to moderate OA who are seeking relief before considering more invasive options like joint replacement surgery. As the aging population continues to grow and OA becomes more prevalent, the demand for viscosupplementation treatments in osteoarthritis is expected to remain strong.

Hospitals Segment is Largest End-Use Industry Due to High Patient Volume and Comprehensive Care

The hospitals segment is the largest end-use industry in the viscosupplementation market, driven by the high volume of patients seeking treatment for joint pain, particularly those with osteoarthritis and sports injuries. Hospitals are equipped with advanced diagnostic and treatment facilities, making them the go-to destination for patients requiring viscosupplementation injections. The availability of specialized orthopedic departments and experienced medical professionals further supports the growth of this segment. Hospitals also offer comprehensive care, from initial diagnosis to post-treatment monitoring, ensuring patients receive optimal care and follow-up services.

In addition to serving as a primary setting for viscosupplementation treatments, hospitals are also increasingly adopting innovative therapies and technologies to improve patient outcomes. As the demand for minimally invasive pain management options continues to rise, hospitals will remain a key player in the viscosupplementation market, catering to both the aging population and active individuals suffering from joint pain.

North America is Largest Region Owing to Advanced Healthcare Infrastructure and High Incidence of Joint Disorders

North America is the largest region in the viscosupplementation market, primarily due to its advanced healthcare infrastructure, high healthcare expenditure, and the rising prevalence of joint-related disorders, particularly osteoarthritis. The United States, in particular, has a large aging population and a high incidence of chronic conditions such as osteoarthritis, which significantly drives demand for viscosupplementation treatments. The availability of well-established healthcare systems, along with a strong focus on research and development, ensures that North America remains at the forefront of the viscosupplementation market.

Additionally, the increasing preference for non-surgical treatment options, coupled with the adoption of minimally invasive procedures, further contributes to the dominance of North America in this market. The region’s well-developed healthcare infrastructure, combined with a high level of awareness about joint health and the benefits of viscosupplementation, positions North America as the largest market for these treatments.

Competitive Landscape

The viscosupplementation market is highly competitive, with several key players dominating the space. Prominent companies include Sanofi, HyalonX, Zimmer Biomet, OrthogenRx, and Anika Therapeutics, among others. These companies are focusing on expanding their product portfolios and improving the efficacy of viscosupplementation injections, particularly with hyaluronic acid-based products. Ongoing research and development activities are central to the competitive dynamics of the market, as manufacturers seek to introduce innovative formulations that offer better results and longer-lasting effects.

Strategic partnerships, acquisitions, and collaborations are common in the market, as companies aim to strengthen their position and enhance their product offerings. The competitive landscape is expected to remain dynamic, with companies continuously striving to improve their products to meet the growing demand for effective, non-invasive treatments for joint pain management. As the market expands, competition will intensify, driving innovation and improving outcomes for patients with joint-related conditions.

Recent Developments:

• Zimmer Biomet launched a new generation of viscosupplementation injection products aimed at providing longer-lasting joint pain relief for osteoarthritis patients.
• AbbVie Inc. received FDA approval for its new hyaluronic acid-based viscosupplementation injection, offering faster recovery times for patients with joint pain.
• Medtronic PLC entered into a partnership with a biotechnology company to develop a novel viscosupplementation treatment for sports-related knee injuries.
• Sanofi S.A. expanded its portfolio by acquiring a viscosupplementation product aimed at patients with severe knee osteoarthritis, enhancing their pain management options.
• Anika Therapeutics, Inc. announced the launch of a new viscosupplementation product designed for improved patient outcomes in post-surgical recovery and joint restoration.

List of Leading Companies:

• Zimmer Biomet
• Sanofi S.A.
• Johnson & Johnson
• AbbVie Inc.
• Ferring Pharmaceuticals
• Medtronic PLC
• Seikagaku Corporation
• Smith & Nephew PLC
• Mylan N.V.
• Eppendorf AG
• B. Braun Melsungen AG
• Regen Lab SA
• OrthogenRx, Inc.
• Bioventus Inc.
• Anika Therapeutics, Inc.

Report Scope: